These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26377306)

  • 1. A phase II study on the efficacy and safety of procedural analgesia with fentanyl buccal tablet in cancer patients for the placement of indwelling central venous access systems.
    Bortolussi R; Zotti P; Matovic M; Morabito A; Bertuzzi C; Caserta M; Fabiani F; Fracasso A; Santantonio C; Zanier C; Roscetti A; Polesel J; Gussetti D; Bedin S; Colussi AM; Fantin D
    Support Care Cancer; 2016 Apr; 24(4):1537-43. PubMed ID: 26377306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
    Masel EK; Landthaler R; Gneist M; Watzke HH
    Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
    Kleeberg UR; Davies A; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Eur J Pain; 2015 Apr; 19(4):528-37. PubMed ID: 25181451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
    Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
    Mercadante S
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
    Portenoy RK; Taylor D; Messina J; Tremmel L
    Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
    Zeppetella G; Messina J; Xie F; Slatkin NE
    Pain Pract; 2010; 10(4):287-93. PubMed ID: 20230447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
    Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
    Slatkin NE; Xie F; Messina J; Segal TJ
    J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
    Mercadante S; Ferrera P; Arcuri E
    Support Care Cancer; 2011 Mar; 19(3):435-8. PubMed ID: 20882391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study.
    Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
    Clin Drug Investig; 2007; 27(9):605-11. PubMed ID: 17705569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
    Weinstein SM; Messina J; Xie F
    Cancer; 2009 Jun; 115(11):2571-9. PubMed ID: 19373888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
    Davies A; Kleeberg UR; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Support Care Cancer; 2015 Jul; 23(7):2135-43. PubMed ID: 25556611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
    Kwon MY; Cho HN; Koo DH; Lee YG; Oh S; Lee SS
    Korean J Intern Med; 2018 May; 33(3):577-584. PubMed ID: 28111431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
    De Franceschi L; Mura P; Schweiger V; Vencato E; Quaglia FM; Delmonte L; Evangelista M; Polati E; Olivieri O; Finco G
    Pain Pract; 2016 Jul; 16(6):680-7. PubMed ID: 26009799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.
    Farrar JT; Messina J; Xie F; Portenoy RK
    Pain Med; 2010 Sep; 11(9):1313-27. PubMed ID: 20807345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.